Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Myelodysplastic Syndromes • Internal Medicine • Hematology
Will you use or have you been using the IPSS-M as the primary way to risk-stratify patients with MDS to determine use of hypomethylating agents?
Will you be using the IPSS-M in place of the IPSS-R? How will you be using IPSS-M in practice?
Answer from: Medical Oncologist at Academic Institution
For the last 10 years, the IPSS-R has been the gold standard for risk stratification of patients with MDS. It is used by the NCCN guidelines to split patients into lower or higher risk groups, each with its own distinct treatment recommendations. The IPSS-R has been used to select patients for clini...
Sign in or Register to read more